# INDP (Indaptus Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Indaptus Therapeutics, Inc. reported $31.21M in total assets and a net loss of $13.50M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/INDP
- Markdown: https://convexityos.com/fundamentals/INDP.md
- SEC CIK: 0001857044
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:39 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001857044&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$13.26M | Operating profit |
| Net Income | FY 2025 | -$13.50M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.10 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $30.60M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $9.34M | $7.25M | $7.62M | $6.32M | $2.52M | $2.66M |
| Total Operating Expenses | $19.83M | $15.37M | $16.38M | $14.91M | $7.73M | $3.60M |
| **Operating Income** | -$19.83M | -$15.37M | -$16.38M | -$14.91M | -$7.73M | -$3.60M |
| **EBITDA** | -- | -$15.37M | -$16.38M | -$14.91M | -$7.73M | -$3.60M |
| Income Before Tax | -$20.85M | -$15.02M | -- | -- | -- | -- |
| Income Tax Expense | $1.7K | $1.7K | $2.5K | $30 | $1.6K | $800 |
| **Net Income** | -$20.85M | -$15.02M | -$15.42M | -$14.32M | -$7.71M | -$3.58M |
| Basic EPS | -$21.58 | -$44.96 | -$51.26 | -$48.46 | -$52.94 | -$51.54 |
| **Diluted EPS** | -$21.58 | -$44.96 | -$51.26 | -$48.46 | -$52.94 | -$51.54 |
| Basic Shares Outstanding | 966.1K | 334.1K | 299.9K | 295.0K | 146.0K | 69.4K |
| Diluted Shares Outstanding | 966.1K | 334.1K | 299.9K | 295.0K | 146.0K | 69.4K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $271K | $363K | $491K | $2.85M | $1.52M | $2.17M | $2.81M | $2.48M |
| Total Operating Expenses | $1.14M | $1.81M | $2.16M | $8.16M | $2.65M | $4.46M | $4.57M | $4.17M |
| **Operating Income** | -$1.14M | -$1.81M | -$2.16M | -$8.16M | -$2.65M | -$4.46M | -$4.57M | -$4.17M |
| **EBITDA** | -- | -- | -- | -- | -- | -- | -- | -$4.17M |
| **Net Income** | -$1.05M | -$1.79M | -$2.54M | -$8.11M | -$2.98M | -$5.23M | -$4.53M | -$4.13M |
| Basic EPS | -$0.01 | -$0.02 | -$0.23 | -- | -$2.98 | -$9.09 | -$9.11 | -- |
| **Diluted EPS** | -$0.01 | -$0.02 | -$0.23 | -- | -$2.98 | -$9.09 | -$9.11 | -- |
| Basic Shares Outstanding | 133.2M | 116.1M | 11.0M | -- | 997.0K | 574.9K | 497.8K | -- |
| Diluted Shares Outstanding | 133.2M | 116.1M | 11.0M | -- | 997.0K | 574.9K | 497.8K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $8.51M | $5.79M | $13.36M | $9.63M | $39.13M | $1.64M |
| Short-Term Investments | -- | -- | -- | $16.81M | -- | -- |
| **Cash & Short-Term Investments** | $8.51M | $5.79M | $13.36M | $26.43M | $39.13M | $1.64M |
| **Total Current Assets** | $9.31M | $6.62M | $14.00M | $27.24M | $40.39M | $1.73M |
| Property, Plant & Equipment, Net | -- | -- | $735 | $2.0K | $3.8K | $1.3K |
| Other Non-Current Assets | -- | $638K | $755K | $738K | $16K | $44K |
| **Total Non-Current Assets** | $0 | $720K | $929K | $820K | $189K | $46K |
| **Total Assets** | $9.31M | $7.34M | $14.92M | $28.06M | $40.58M | $1.78M |
| Accounts Payable | $544K | $870K | $806K | $1.38M | $2.54M | $156K |
| **Total Current Liabilities** | $6.16M | $3.39M | $2.77M | $3.43M | $4.60M | $2.02M |
| Other Non-Current Liabilities | -- | -- | -- | -- | -- | $691K |
| **Total Non-Current Liabilities** | $0 | $0 | $73K | $0 | $73K | $1.03M |
| **Total Liabilities** | $6.16M | $3.39M | $2.85M | $3.43M | $4.68M | $2.02M |
| **Total Debt (incl. Leases)** | -- | $84K | $175K | $80K | $169K | $934K |
| Common Stock | $22K | $4.3K | $84K | $84K | $83K | $19K |
| Retained Earnings | -$81.29M | -$60.44M | -$45.42M | -$29.99M | -$15.67M | -$7.96M |
| Accumulated Other Comp. Income | -- | -- | -- | $96K | -- | -- |
| **Total Stockholders' Equity** | $3.15M | $3.94M | $12.08M | $24.63M | $35.90M | -$238K |
| Total Equity | $3.15M | $3.94M | $12.08M | $24.63M | $35.90M | -$238K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $26.60M | $7.55M | $8.51M | $5.83M | $6.16M | $3.89M | $5.79M | $7.38M |
| Short-Term Investments | $4.00M | $4.00M | -- | -- | -- | -- | -- | -- |
| **Cash & Short-Term Investments** | $30.60M | $11.55M | $8.51M | $5.83M | $6.16M | $3.89M | $5.79M | $7.38M |
| Other Current Assets | $27K | $28K | -- | -- | -- | -- | -- | -- |
| **Total Current Assets** | -- | -- | $9.31M | $6.44M | $6.41M | $4.96M | $6.62M | $7.63M |
| Other Non-Current Assets | -- | -- | -- | $393K | $393K | $393K | $638K | $505K |
| **Total Non-Current Assets** | -- | -- | $0 | $401K | $426K | $451K | $720K | $610K |
| **Total Assets** | $31.21M | $11.99M | $9.31M | $6.84M | $6.84M | $5.41M | $7.34M | $8.24M |
| Accounts Payable | $172K | $509K | $544K | $707K | $619K | $1.31M | $870K | $556K |
| **Total Current Liabilities** | -- | -- | $6.16M | $2.23M | $8.51M | $2.61M | $3.39M | $2.23M |
| **Total Non-Current Liabilities** | -- | -- | $0 | $0 | $0 | $0 | $0 | $4.0K |
| **Total Liabilities** | $20.88M | $615K | $6.16M | $2.23M | $8.51M | $2.61M | $3.39M | $2.24M |
| **Total Debt (incl. Leases)** | -- | -- | -- | $8.7K | $34K | $60K | $84K | $108K |
| Common Stock | $1.33M | $1.33M | $22K | $16K | $6.0K | $160K | $4.3K | $102K |
| Retained Earnings | -$86.67M | -$85.62M | -$81.29M | -$73.18M | -$70.20M | -$64.97M | -$60.44M | -$56.31M |
| **Total Stockholders' Equity** | $10.33M | $11.37M | $3.15M | $4.61M | -$1.67M | $2.80M | $3.94M | $6.00M |
| Total Equity | $10.33M | $11.37M | $3.15M | $4.61M | -$1.67M | $2.80M | $3.94M | $6.00M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$20.85M | -$15.02M | -$15.42M | -$14.32M | -$7.71M | -$3.58M |
| Depreciation & Amortization | -- | $735 | $1.3K | $1.8K | $1.4K | $852 |
| Stock-Based Compensation | $1.36M | $2.31M | $2.97M | $2.96M | $1.51M | $140K |
| **Operating Cash Flow** | -$14.82M | -$12.32M | -$13.41M | -$13.08M | -$11.29M | -$3.32M |
| Capital Expenditure | -- | -- | -- | -- | -$3.9K | -- |
| **Free Cash Flow** | -- | -- | -- | -- | -$11.29M | -- |
| Purchases of Investments | -- | -- | -$6.86M | -$29.60M | -- | -- |
| **Investing Cash Flow** | -- | -- | $17.14M | -$16.43M | $448K | -- |
| Common Stock Issued | $6.40M | $5.51M | -- | -- | -- | -- |
| **Financing Cash Flow** | $17.54M | $4.75M | -- | -- | $48.34M | $1.16M |
| **Net Change in Cash** | $2.72M | -$7.58M | $3.74M | -$29.51M | $37.49M | -$2.16M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.05M | -$1.79M | -$2.54M | -$8.11M | -$2.98M | -$5.23M | -$4.53M | -$4.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | $0 |
| Stock-Based Compensation | $8.4K | -$64K | $227K | $786K | $151K | $181K | $241K | $304K |
| **Operating Cash Flow** | -$1.44M | -$1.93M | -$7.01M | -$3.19M | -$2.57M | -$4.02M | -$5.05M | -$3.40M |
| Common Stock Issued | -- | -- | -- | -$154 | $2.34M | $575K | $3.48M | $2.14M |
| **Financing Cash Flow** | -- | -- | -- | $5.87M | $2.24M | $6.28M | $3.15M | $1.80M |
| **Net Change in Cash** | $19.05M | $6.06M | -$7.01M | $2.68M | -$332K | $2.27M | -$1.90M | -$1.59M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -661.5% | -380.8% | -127.7% | -58.2% | -21.5% | -- |
| Return on Assets (ROA) | -223.9% | -204.7% | -103.3% | -51.0% | -19.0% | -201.6% |
| Current Ratio | 1.51x | 1.95x | 5.05x | 7.94x | 8.77x | 0.86x |
| Quick Ratio | 1.38x | 1.71x | 4.82x | 7.70x | 8.50x | 0.81x |
| Debt to Equity | -- | 0.02x | 0.01x | 0.00x | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -130.6% | -135.6% | -- | -661.5% | -366.2% | -- | -562.5% | -380.8% |
| Return on Assets (ROA) | -43.2% | -128.7% | -- | -223.9% | -246.6% | -248.0% | -291.0% | -204.7% |
| Current Ratio | -- | -- | -- | 1.51x | 2.88x | 0.75x | 1.90x | 1.95x |
| Quick Ratio | -- | -- | -- | 1.38x | 2.61x | 0.72x | 1.49x | 1.71x |
| Debt to Equity | -- | -- | -- | -- | 0.00x | -- | 0.02x | 0.02x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
